Skip to main content
. 2024 Nov 5;18:313–326. doi: 10.2147/BTT.S489363

Figure 2.

Figure 2

Waterfall plot for the response in target lesion of the 56 subjects with advanced non-small cell lung cancer who received anlotinib plus PD-1 inhibitors. (Blue columns mean PR, black columns mean SD and red column represents PD).